Summary
Esthesioneuroblastoma is an uncommon malignancy of the nasal vault with a treatment regimen consisting of surgical resection followed by radiotherapy for primary lesions and addition of chemotherapy for patients with advanced, recurrent or metastatic lesions. We report a case of a 39-year-old female with a history of esthesioneuroblastoma, previously treated with resection, radiation and chemotherapy, presenting with a recurrent disease that was successfully treated with re-resection and placement of Gliadel® wafers in the surgical resection cavity. The novel option of controlled-release and local delivery of a chemotherapeutic agent for treatment of recurrent esthesioneuroblastoma should be recognized and considered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berger L, Luc et Richard: L’esthesioneuroepitheliome olfactif. Bull Assoc Fr Etude Cancer 13: 410–421, 1924
P Dulguerov, AS Allal and TC Calcaterra, Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2 (2001) 683-690
PJ Bradley, NS Jones and I Robertson, Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolayrngol Head Neck Surg 11 (2003) 112-118
P Sampath and H Brem, Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 5 (1998) 130-137
H Brem and P Gabikian, Biodegradable polymer implants to treat brain tumors. J Control Release 74 (2001) 63-67
Brem H, Piantadosi S, Burger PC, Walker M, Selker K, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC: for the polymer-brain tumor treatment group: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345: 1008–1012, 1995
M Westphal, DC Hilt, E Bortey, P Delavault, R Olivares, PC Warnke, IR Whittle, J Jaaskelainen and Z Ram, A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel® wafers) in patients with primary malignant glioma. Neuro-oncol 5 (2003) 79-88
ER Laws Jr, AM Morris and N Maartens, Gliadel for pituitary adenomas and craniopharyngiomas. Neurosurgery 53 (2003) 255-260
C Guerin, A Olivi, JD Weingart, HC Lawson and H Brem, Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 22 (2004) 27-37
JM Sheehan, JP Sheehan, JA Jane Sr and RS Polin, Chemotherapy for esthesioneuroblastomas. Neurosurg Clin of North Am 11 (2000) 693-701
K Watne and B Hager, Treatment of recurrent esthesioneuroblastoma with combined intra-arterial chemotherapy. A case report. J Neurooncol 5 (1987) 47-50
S Kadish, M Goodman and CC Wang, Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 37 (1976) 1571-1576
P Dulguerov and T Calcaterra, Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope 102 (1992) 843-849
VJ Hyams, Olfactory neuroblastoma. In: VJ, Hyams, JG Baksakis and L Michaels (eds.) Tumors of the Upper Respiratory Tract and Ear. Washington DC: Armed Forces Institute of Pathology (1988) pp. 240-248
G Broich, A Pagliari and F Ottaviani, Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 17 (1997) 2683-2706
A Morita, MJ Ebersold, KD Olsen, RL Foote, JE Lewis and LM Quast, Esthesioneuroblastoma: prognosis and management. Neurosurgery 32 (1993) 706-715
HF Biller, W Lawson, VP Sachdev and P Som, Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope 100 (1990) 1199-1201
FL Dias, GM Sa, RA Lima, J Kligerman, MP Leoncio, EQ Freitas, JR Soares and RA Arcuri, Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 129 (2003) 1186-1192
D Elkon, SI Hightower, ML Lim, RW Cantrell and WC Constable, Esthesioneuroblastoma. Cancer 44 (1979) 1087-1094
BV Eden, RF Debo, JM Larner, MD Kelly, PA Levine, FM Stewart, RW Cantrell and WC Constable, Esthesioneuroblastoma. Long-term outcome and patterns of failure – the University of Virginia experience. Cancer 73 (1994) 2556-2562
PA Levine, R Gallagher and RW Cantrell, Esthesioneuroblastoma: reflections of a 21-year experience. Laryngoscope 109 (1999) 1539-1543
VA Resto, DW Eisele, A Forastiere, M Zahurak, DJ Lee and WH Westra, Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck 22 (2000) 550-558
KS Chao, C Kaplan, JR Simpson, B Haughey, GJ Spector, DG Sessions and M Arquette, Esthesioneuroblastoma: the impact of treatment modality. Head Neck 23 (2001) 749-757
J Constantinidis, H Steinhart, M Koch, M Buchfelder, A Schaenzer, M Weidenbecher and H Iro, Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975–2000. Otolayrngol Head Neck Surg 130 (2004) 567-574
EA McElroy Jr., JC Buckner and JE Lewis, Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 42 (1998) 1023-1028
RS Polin, JP Sheehan, AG Chenell, E Munoz, J Larner, CD Phillips, RW Cantrell, ER Laws Jr, SA Newman, PA Levine and JA Jane, The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery 42 (1998) 1029-1037
DW Kim, YH Jo, JH Kim, HG Wu, CS Rhee, CH Lee, TY Kim, DS Heo, YJ Bang and NK Kim, Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 101 (2004) 2257-2260
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, M.C., Weaver Jr, C.E., Donahue, J.E. et al. Intracavitary chemotherapy (Gliadel®) for recurrent esthesioneuroblastoma: case report and review of the literature. J Neurooncol 77, 47–51 (2006). https://doi.org/10.1007/s11060-005-7411-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-005-7411-y